Switch to:
Also traded in: Germany, Japan
» Details

Insider Trades

Latest Guru Trades with DSNKY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major  
Compare:OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:KYKOF, OTCPK:CHJTF, OTCPK:OTSKY, OTCPK:SNPHY, OTCPK:PTKFY, OTCPK:GWPRF, OTCPK:ALPMY, NAS:HCM, OTCPK:MAYNF, OTCPK:HAWPF, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:ASMB, NAS:RMTI, NAS:NBRV, NAS:ZGNX, OTCPK:AGYTF » details
Traded in other countries:D4S.Germany, 4568.Japan,
Daiichi Sankyo Co Ltd., manufactures pharmaceuticals for human & veterinary use and medical tools and equipment. The Company also researches and promotes products through related companies.

Daiichi Sankyo Co Ltd was founded on September 28, 2005. The Company is engaged in the research, development, manufacture, sale and marketing of pharmaceutical products. Its principal products include Olmesartan, an anti-hypertensive agent; Prasugrel, an antiplatelet agent; Memary and Donepezil for the treatment of alzheimer's disease; Nexium for treating reflux esophagitis; Inavir, an anti-influenza treatment product; ActHIB, a haemophilus b conjugate vaccine; and Loxonin S, an analgesic and anti-inflammatory drug; Denosumab, an antibody for the treatment and prevention of various bone disorders; and Edoxaban, an oral anticoagulant product. The Company also markets therapies in hypertension, dyslipidemia, diabetes, acute coronary syndrome, and metastatic melanoma.

Ratios

vs
industry
vs
history
P/E(ttm) 28.68
DSNKY's P/E(ttm) is ranked lower than
53% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.40 vs. DSNKY: 28.68 )
Ranked among companies with meaningful P/E(ttm) only.
DSNKY' s P/E(ttm) Range Over the Past 10 Years
Min: 4.1  Med: 18.54 Max: 177.39
Current: 28.68
4.1
177.39
PE(NRI) 28.68
DSNKY's PE(NRI) is ranked lower than
52% of the 543 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.84 vs. DSNKY: 28.68 )
Ranked among companies with meaningful PE(NRI) only.
DSNKY' s PE(NRI) Range Over the Past 10 Years
Min: 10.38  Med: 19.72 Max: 177.39
Current: 28.68
10.38
177.39
Price/Owner Earnings (ttm) 37.04
DSNKY's Price/Owner Earnings (ttm) is ranked lower than
59% of the 300 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.72 vs. DSNKY: 37.04 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
DSNKY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 4.24  Med: 21.54 Max: 149.36
Current: 37.04
4.24
149.36
P/B 1.44
DSNKY's P/B is ranked higher than
79% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.02 vs. DSNKY: 1.44 )
Ranked among companies with meaningful P/B only.
DSNKY' s P/B Range Over the Past 10 Years
Min: 0.92  Med: 1.33 Max: 1.61
Current: 1.44
0.92
1.61
P/S 1.81
DSNKY's P/S is ranked higher than
68% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.06 vs. DSNKY: 1.81 )
Ranked among companies with meaningful P/S only.
DSNKY' s P/S Range Over the Past 10 Years
Min: 0.87  Med: 1.34 Max: 11.5
Current: 1.81
0.87
11.5
PFCF 16.62
DSNKY's PFCF is ranked higher than
67% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.72 vs. DSNKY: 16.62 )
Ranked among companies with meaningful PFCF only.
DSNKY' s PFCF Range Over the Past 10 Years
Min: 8.99  Med: 17.52 Max: 352.13
Current: 16.62
8.99
352.13
POCF 10.93
DSNKY's POCF is ranked higher than
69% of the 295 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.98 vs. DSNKY: 10.93 )
Ranked among companies with meaningful POCF only.
DSNKY' s POCF Range Over the Past 10 Years
Min: 7.06  Med: 10.83 Max: 271.69
Current: 10.93
7.06
271.69
EV-to-EBIT 10.82
DSNKY's EV-to-EBIT is ranked higher than
82% of the 574 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.65 vs. DSNKY: 10.82 )
Ranked among companies with meaningful EV-to-EBIT only.
DSNKY' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.9  Med: 9.9 Max: 136.8
Current: 10.82
-4.9
136.8
EV-to-EBITDA 7.85
DSNKY's EV-to-EBITDA is ranked higher than
88% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.72 vs. DSNKY: 7.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
DSNKY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 7.9 Max: 136.8
Current: 7.85
4.8
136.8
PEG 13.00
DSNKY's PEG is ranked lower than
93% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. DSNKY: 13.00 )
Ranked among companies with meaningful PEG only.
DSNKY' s PEG Range Over the Past 10 Years
Min: 0.73  Med: 1.16 Max: 13.38
Current: 13
0.73
13.38
Shiller P/E 19.21
DSNKY's Shiller P/E is ranked higher than
85% of the 158 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 47.37 vs. DSNKY: 19.21 )
Ranked among companies with meaningful Shiller P/E only.
DSNKY' s Shiller P/E Range Over the Past 10 Years
Min: 16.32  Med: 17.68 Max: 19.4
Current: 19.21
16.32
19.4
Current Ratio 3.39
DSNKY's Current Ratio is ranked higher than
63% of the 726 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.49 vs. DSNKY: 3.39 )
Ranked among companies with meaningful Current Ratio only.
DSNKY' s Current Ratio Range Over the Past 10 Years
Min: 1.54  Med: 2.64 Max: 4.15
Current: 3.39
1.54
4.15
Quick Ratio 2.94
DSNKY's Quick Ratio is ranked higher than
66% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.84 vs. DSNKY: 2.94 )
Ranked among companies with meaningful Quick Ratio only.
DSNKY' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 2.14 Max: 3.58
Current: 2.94
1.27
3.58
Days Inventory 171.64
DSNKY's Days Inventory is ranked lower than
75% of the 687 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. DSNKY: 171.64 )
Ranked among companies with meaningful Days Inventory only.
DSNKY' s Days Inventory Range Over the Past 10 Years
Min: 157.9  Med: 185.44 Max: 234.37
Current: 171.64
157.9
234.37

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.59
DSNKY's Dividend Yield is ranked higher than
71% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. DSNKY: 2.59 )
Ranked among companies with meaningful Dividend Yield only.
DSNKY' s Dividend Yield Range Over the Past 10 Years
Min: 2.25  Med: 3.55 Max: 6.91
Current: 2.59
2.25
6.91
Dividend Payout 0.70
DSNKY's Dividend Payout is ranked lower than
79% of the 375 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.36 vs. DSNKY: 0.70 )
Ranked among companies with meaningful Dividend Payout only.
DSNKY' s Dividend Payout Range Over the Past 10 Years
Min: 0.5  Med: 0.62 Max: 4.07
Current: 0.7
0.5
4.07
Forward Dividend Yield 2.68
DSNKY's Forward Dividend Yield is ranked higher than
75% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. DSNKY: 2.68 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.60
DSNKY's Yield on cost (5-Year) is ranked higher than
59% of the 764 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.14 vs. DSNKY: 2.60 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DSNKY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.25  Med: 3.55 Max: 6.91
Current: 2.6
2.25
6.91
3-Year Average Share Buyback Ratio 1.00
DSNKY's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 436 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. DSNKY: 1.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DSNKY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.7  Med: 0.3 Max: 1.9
Current: 1
-18.7
1.9

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 3.86
DSNKY's Price/Net Current Asset Value is ranked higher than
75% of the 542 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. DSNKY: 3.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DSNKY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.97  Med: 6.51 Max: 24.82
Current: 3.86
2.97
24.82
Price/Tangible Book 1.91
DSNKY's Price/Tangible Book is ranked higher than
74% of the 747 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.65 vs. DSNKY: 1.91 )
Ranked among companies with meaningful Price/Tangible Book only.
DSNKY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.3  Med: 1.77 Max: 2.03
Current: 1.91
1.3
2.03
Price/Projected FCF 1.30
DSNKY's Price/Projected FCF is ranked higher than
78% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.66 vs. DSNKY: 1.30 )
Ranked among companies with meaningful Price/Projected FCF only.
DSNKY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.95  Med: 1.14 Max: 1.35
Current: 1.3
0.95
1.35
Price/Median PS Value 1.36
DSNKY's Price/Median PS Value is ranked lower than
62% of the 703 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. DSNKY: 1.36 )
Ranked among companies with meaningful Price/Median PS Value only.
DSNKY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.7  Med: 1.04 Max: 7.3
Current: 1.36
0.7
7.3
Price/Peter Lynch Fair Value 1.15
DSNKY's Price/Peter Lynch Fair Value is ranked higher than
67% of the 168 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. DSNKY: 1.15 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
DSNKY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.59  Med: 1.59 Max: 3.56
Current: 1.15
0.59
3.56
Price/Graham Number 1.56
DSNKY's Price/Graham Number is ranked higher than
67% of the 443 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.25 vs. DSNKY: 1.56 )
Ranked among companies with meaningful Price/Graham Number only.
DSNKY' s Price/Graham Number Range Over the Past 10 Years
Min: 1  Med: 1.23 Max: 3.57
Current: 1.56
1
3.57
Earnings Yield (Greenblatt) (%) 9.26
DSNKY's Earnings Yield (Greenblatt) (%) is ranked higher than
88% of the 835 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.00 vs. DSNKY: 9.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DSNKY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.7  Med: 9.7 Max: 15.5
Current: 9.26
0.7
15.5
Forward Rate of Return (Yacktman) (%) 38.04
DSNKY's Forward Rate of Return (Yacktman) (%) is ranked higher than
90% of the 358 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.67 vs. DSNKY: 38.04 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
DSNKY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -22.7  Med: 1.75 Max: 38.2
Current: 38.04
-22.7
38.2

More Statistics

Revenue (TTM) (Mil) $8,820
EPS (TTM) $ 0.84
Beta0.82
Short Percentage of Float0.00%
52-Week Range $19.57 - 26.24
Shares Outstanding (Mil)683.39
» More Articles for OTCPK:DSNKY

Headlines

Articles On GuruFocus.com
Brandes Investment Partners Comments on Daiichi Sankyo Sep 16 2015 
Brandes Global Equity Fund Second Quarter 2015 Commentary Sep 16 2015 

More From Other Websites
Daiichi Sankyo and ArQule Announce the Completion of the METIV-HCC Phase 3 Study of Tivantinib in... Feb 17 2017
Japan Inc.'s Raw Indian Deal Jan 23 2017
Kite Pharma Inks Deals for CAR T Cell Drug in Japan, China Jan 10 2017
Kite Pharma Establishes a Strategic Partnership With Daiichi Sankyo to Develop and Commercialize... Jan 09 2017
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR... Nov 21 2016
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR... Nov 21 2016
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday,... Nov 11 2016
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on Thursday,... Nov 11 2016
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual... Nov 10 2016
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual... Nov 10 2016
Astellas Pharma Inc. -- Moody's: Japanese pharmaceutical companies' expiring drugs patents could... Oct 19 2016
Zymeworks and Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement and Bi-Specific... Sep 28 2016
Exelixis Announces Collaborator Daiichi Sankyo’s Initiation of Phase 3 Clinical Development for... Sep 26 2016
Daiichi Sankyo Selects Veeva Vault to Streamline Submissions, eTMF, and Quality Management Aug 23 2016
Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan Jul 14 2016
Amgen And Daiichi Sankyo Announce Agreement To Commercialize Biosimilars In Japan Jul 13 2016
Daiichi Sankyo Company, Limited -- Moody's assigns (P)A1 to Daiichi Sankyo's domestic shelf... Jul 07 2016
UCB's Vimpat Approved in Japan for Partial Onset Seizures Jul 06 2016
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR... Jun 13 2016
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR... Jun 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK